Arlington Partners LLC Grows Stake in Johnson & Johnson $JNJ

Key Points

• Arlington Partners LLC increased its stake in Johnson & Johnson by 11.0% during the 2nd quarter, holding 29,010 shares worth approximately $4.43 million.
• Numerous hedge funds have also modified their positions in JNJ, with a reported 69.55% of the stock now owned by institutional investors.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, yielding around 3.0%, reflecting a dividend payout ratio of 55.61%.

Arlington Partners LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 11.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,010 shares of the company's stock after acquiring an additional 2,882 shares during the quarter. Arlington Partners LLC's holdings in Johnson & Johnson were worth $4,431,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Highline Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the first quarter worth approximately $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson during the first quarter worth approximately $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on JNJ. Bank of America upped their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. The Goldman Sachs Group raised their price target on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a report on Friday. Morgan Stanley upped their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Finally, Citigroup upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research note on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $178.80.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $174.22 on Tuesday. The company has a market capitalization of $419.58 billion, a price-to-earnings ratio of 18.63, a P/E/G ratio of 2.24 and a beta of 0.40. The firm's 50 day simple moving average is $173.14 and its 200 day simple moving average is $161.69. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business posted $2.82 earnings per share. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.